Search bioRxiv⌕ Search

Biology subjects

Ward, L. D.

Publications and source records attributed to Ward, L. D..

6 recordsLinked to original sources

Ancestry-specific performance of variant effect predictors in clinical variant classification

Predicting the effects of genetic variants and assessing prediction performance are key computational tasks in genomic medicine. It has been shown that well-calibrated variant effect predictors can be reliably used as evidence towards establishing pathogenicity (or benignity) of missense variants, thereby rendering these variants suitable for use in (or exclusion from) the genetic diagnosis of rare Mendelian conditions. However, most predictors have been trained or calibrated on data that may not be sufficiently representative to lead to similar performance across all genetic ancestries. This raises questions about the responsible deployment of these tools to improve human health. To better understand the utility of computational predictors, we set out to assess their ancestry-specific performance in terms of accuracy and evidence strength according to the ACMG/AMP guidelines. First, we determined that the expected count of rare variants in an individuals genome and the allele frequency distribution of these variants are the key confounders when evaluating a predictors performance across different genetic ancestries. Second, we found that a predictors accuracy itself inversely correlates with the allele frequency of the rare variant. After stratifying according to allele frequency, we show that established methods for predicting the pathogenicity of missense variants have comparable performance levels across major ancestry groups. Our results therefore support the wide deployment of such models in the context of genetic diagnosis and related applications.

bioinformatics↗

High-throughput plasma proteomic platforms: Insights from a multi-ethnic Asian cohort

We compared three leading affinity-based and mass-spectrometry-based proteomic platforms (SomaScan11K, Olink Explore HT, Orbitrap Astral with Seer Proteograph [MS-Seer]) in a multi-ethnic Asian cohort, to inform biomarker discovery and functional genomic studies of global populations. We found limited overlap (1,740 proteins) across the three platforms, with modest correlations (0.34-0.10). SomaScan had lower missingness (<1%) and CV (<10%), compared to Olink (51%, 23%) and MS-Seer (12%, 19%). The new assays in Olink Explore HT (absent in Explore3072) primarily drove its higher missingness and CV. The number of phenotypic associations varied by trait, while the number of genetic associations (cis-pQTLs at P<5e-08) were similar for Olink and SomaScan. Protein levels differed between ethnicities, with SomaScan identifying more ethnicity-differentiated proteins than Olink (FDR<0.05). Finally, SomaScan ANML normalization attenuated biologically relevant associations in our study. These findings underscore the importance of platform evaluation and data normalization strategies for application in large-scale, diverse population cohorts.

bioinformatics↗

Genetic regulation of the human plasma proteome in 54,306 UK Biobank participants

The UK Biobank Pharma Proteomics Project (UKB-PPP) is a collaboration between the UK Biobank (UKB) and thirteen biopharmaceutical companies characterising the plasma proteomic profiles of 54,306 UKB participants. Here, we describe results from the first phase of UKB-PPP, including protein quantitative trait loci (pQTL) mapping of 1,463 proteins that identifies 10,248 primary genetic associations, of which 85% are newly discovered. We also identify independent secondary associations in 92% of cis and 29% of trans loci, expanding the catalogue of genetic instruments for downstream analyses. The study provides an updated characterisation of the genetic architecture of the plasma proteome, leveraging population-scale proteomics to provide novel, extensive insights into trans pQTLs across multiple biological domains. We highlight genetic influences on ligand-receptor interactions and pathway perturbations across a diverse collection of cytokines and complement proteins, and illustrate long-range epistatic effects of ABO blood group and FUT2 secretor status on proteins with gastrointestinal tissue-enriched expression. We demonstrate the utility of these data for drug target discovery by extending the genetic proxied effect of PCSK9 levels on lipid concentrations, cardio- and cerebro-vascular diseases, and additionally disentangle specific genes and proteins perturbed at COVID-19 susceptibility loci. This public-private partnership provides the scientific community with an open-access proteomics resource of unprecedented breadth and depth to help elucidate biological mechanisms underlying genetic discoveries and accelerate the development of novel biomarkers and therapeutics.

genetics↗

A Proteomic Platform to Identify Off-Target Proteins Associated with Therapeutic Modalities that Induce Protein Degradation or Gene Silencing

Novel modalities such as Proteolysis Targeting Chimera (PROTAC) and RNA interference (RNAi) have a mechanism of action-based potential to alter the abundance of off-target proteins. The current in vitro secondary pharmacology assays, which evaluate off-target binding or activity of small molecules, do not fully assess the off-target effects of PROTAC and are not applicable to RNAi. To address this gap, we developed a proteomics-based platform to comprehensively evaluated abundance of off-target proteins. The first part of the manuscript describes the rationale and process through which the off-target proteins and cell lines were selected. The off-target proteins were selected from the entire human proteome based on genetics and pharmacology data (Deaton et al., 2018). The selection yielded 2,813 proteins, forming the nexus of a panel that we refer to as the "selected off-target proteome" (SOTP). An algorithm was then used to identify appropriate cell lines. Four human cell lines out of 932 were selected that, collectively, expressed ~ 80% of the SOTP based on transcriptome data. The second part of the manuscript describes the LC-MS/MS experimentation to quantify the intracellular and extracellular proteins of interest in the 4 selected cell lines. Among over 10,000 quantifiable proteins identified, 1,828 were part of the predefined SOTP. The SOTP was designed to be easily modified or expanded, owing rationale selection process developed and the label free LC-MS/MS approach chosen. This versatility inherent to our platform is essential to design fit-for-purpose studies that can address the dynamic questions faced in investigative toxicology.

pharmacology and toxicology↗

Genome-wide association study of circulating liver enzymes reveals an expanded role for manganese transporter SLC30A10 in liver health

To investigate mechanisms of hepatocellular damage, we performed genome-wide association studies (GWAS) on alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serum activities across 411,048 subjects from four ancestry groups in the UK Biobank, and found 100 loci associating with both enzymes. The rare missense variant SLC30A10 Thr95Ile (rs188273166) associates with a larger elevation in ALT and AST than any other variant tested and this association also replicates in the DiscovEHR study. SLC30A10 excretes manganese from the liver to the bile duct, and rare homozygous loss of function causes the syndrome hypermanganesemia with dystonia-1 (HMNDYT1) which involves cirrhosis. Consistent with hematological symptoms of hypermanganesemia, SLC30A10 Thr95Ile carriers have increased hematocrit and risk of iron deficiency anemia. Carriers also have increased risk of extrahepatic bile duct cancer. These associations suggest that genetic variation in SLC30A10 adversely affects more individuals than patients with diagnosed HMNDYT1.

genetics↗

Phenotypes associated with genes encoding drug targets are predictive of clinical trial side effects

Biomedical scientists face major challenges in developing novel drugs for unmet medical needs. Only a small fraction of early drug programs progress to the market, due to safety and efficacy failures, despite extensive efforts to predict drug and target safety as early as possible using a variety of assays in vitro and in preclinical species. In principle, characterizing the effect of natural variation in the genes encoding drug targets should present a powerful alternate approach to predict not only whether a protein will be an effective drug target, but also whether a protein will be an inherently safe drug target, while avoiding the challenges of translating biology from experiments in non-human species. We have embarked on a retrospective analysis, demonstrating for the first time a statistical link between the organ systems involved in genetic syndromes of drug target genes and the organ systems in which side effects are observed clinically. Across 1,819 drugs and 21 organ system phenotype categories analyzed, drug side effects are more likely to occur in organ systems where there is genetic evidence of a link between the drug target and a phenotype involving that organ system, compared to when there is no such genetic evidence (30.0% vs 19.2%; OR = 1.80). Conversely, we find that having genetic evidence of a Mendelian syndrome involving a drug target in which a certain organ system is unaffected decreases the likelihood that side effects will manifest in that organ system, relative to having no informative syndrome (18.5% vs 20.2%; OR = 0.89). We find a relationship between genetics and side effects even when controlling for known confounders such as drug delivery route and indication. We highlight examples where genetics of drug targets could have anticipated side effects observed during clinical trials. This result suggests that human genetic data should be routinely used to predict potential safety issues associated with novel drug targets. This may lead to selection of better targets, appropriate monitoring of putative side effects early in development, reduction of the use of preclinical animal experiments, and ultimately increased success of molecules. Furthermore, deeply phenotyping human knockouts will be critically important to understand the full spectrum of effects that a new drug may elicit.

genetics↗